

# Special Issue

## Epigenetic Drugs

### Message from the Guest Editor

Many diseases (e.g., cancer, diabetes, heart, mental, and autoimmune diseases) are associated with epigenetic aberrations including DNA methylation, histone post-translational modifications, chromatin remodeling, and regulatory RNA. Until now, the DNMT inhibitors 5-azacytidine and 5-aza-20-deoxycytidine and the HDAC inhibitors belinostat, panobinostat, romidepsin, vorinostat have been approved by the FDA for the treatment of various cancers. Many of these drugs suffer from high toxicity, rapid metabolism, poor bioavailability, and limited effectiveness in monotherapy. However, in combinatorial therapy, they can be beneficial to patients. In this Special Issue, we would like to invite the submission of manuscripts containing new findings, which may contribute to the design and use of new epigenetic drugs with improved activity, functional significance of different epigenetic drugs (or candidates)-induced signaling pathways and their clinical implications, improvement of the new drugs selectivity, identification of new molecular targets of epigenetic drugs and their clinical significance, and potential combined epigenetic therapies.

### Guest Editor

Dr. Marcin Ratajewski

Laboratory of Epigenetics, Institute of Medical Biology of the Polish of Sciences, Lodz, Poland

### Deadline for manuscript submissions

closed (15 December 2021)



## Pharmaceuticals

an Open Access Journal  
by MDPI

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/53350](https://mdpi.com/si/53350)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





# Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)